Taken together, cell-specific responses to tumor-targeting IFN-α-containing-mAbs relate to its sensitivity to IFN-α, the specific mAbs used, as well as the expression and density of the targeted tumor-associated antigens. This evidence concerns the gene IFNA17 and neoplasm.